⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1117681 | 0.92 | LMNA (0.41) | — | |
| SCHEMBL11590715 | 0.90 | LMNA (0.44) | — | |
| SCHEMBL15275667 | 0.90 | LMNA (0.44) | — | |
| SCHEMBL8555513 | 0.90 | LMNA (0.44) | — | |
| SCHEMBL8434310 | 0.90 | LMNA (0.44) | — | |
| SCHEMBL17866338 | 0.90 | LMNA (0.44) | — | |
| SCHEMBL7866873 | 0.90 | LMNA (0.44) | — | |
| SCHEMBL1679221 | 0.89 | CA2 (0.43) | — | |
| SCHEMBL1678453 | 0.84 | PLA2G2C (0.43) | — | |
| SCHEMBL1679051 | 0.84 | CA2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114437334-B | Polyether amine compound, preparation method and application thereof | 中国石油化工股份有限公司 | 2023-07-14 | — | — | CN | claimed |
| WO-1995029892-A1 | HYDROXAMIC ACID AND AMINO ACID DERIVATIVES AND THEIR USE AS ANTI-ARTHRITIC AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-11-09 | — | — | WO | claimed |
| CN-114437334-B | Polyether amine compound, preparation method and application thereof | 中国石油化工股份有限公司 | 2023-07-14 | — | — | CN | disclosed |
| US-7923573-B2 | Benzene compound having 2 or more substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2011-04-12 | — | — | US | disclosed |
| US-20080255111-A1 | Tissue Factor Production Inhibitor | SANKYO COMPANY LIMITED (JP) | 2008-10-16 | — | — | US | disclosed |
| US-20080004301-A1 | Benzene Compound Having 2 or More Substituents | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-01-03 | — | — | US | disclosed |
| EP-1806332-A1 | BENZENE COMPOUND HAVING 2 OR MORE SUBSTITUENTS | Daiichi Sankyo Company, Limited (JP) | 2007-07-11 | — | — | EP | disclosed |
| EP-1764075-A1 | TISSUE FACTOR PRODUCTION INHIBITOR | Sankyo Company, Limited (JP) | 2007-03-21 | — | — | EP | disclosed |
| US-20050020607-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2005-01-27 | — | — | US | disclosed |
| US-20040176393-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2004-09-09 | — | — | US | disclosed |
| EP-1366765-A1 | Use of matrix metalloproteinase inhibitors for treating neurological disorders and promoting wound healing | WARNER-LAMBERT COMPANY LLC (US) | 2003-12-03 | — | — | EP | disclosed |
| EP-1047450-B1 | ACE INHIBITOR-MMP INHIBITOR COMBINATIONS | WARNER LAMBERT CO (US) | 2002-10-02 | — | — | EP | disclosed |
| US-20020049237-A1 | Statin-MMP inhibitor combinations | NEWTON ROGER SCHOFIELD (US) | 2002-04-25 | — | — | US | disclosed |
| US-6340709-B1 | ADMINISTERING BIPHENYLSULFONAMIDE DERIVATIVE | WARNER-LAMBERT COMPANY | 2002-01-22 | — | — | US | disclosed |
| EP-1063991-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY LLC (US) | 2001-01-03 | — | — | EP | disclosed |
| EP-1028716-A1 | METHOD FOR TREATING AND PREVENTING HEART FAILURE AND VENTRICULAR DILATATION | WARNER-LAMBERT COMPANY (US) | 2000-08-23 | — | — | EP | disclosed |
| WO-1999047138-A1 | STATIN-MATRIX METALLOPROTEINASE INHIBITOR COMBINATIONS | WARNER-LAMBERT COMPANY (US) | 1999-09-23 | — | — | WO | disclosed |
| WO-1998025597-A2 | METHOD FOR TREATING AND PREVENTING HEART FAILURE AND VENTRICULAR DILATATION | WARNER-LAMBERT COMPANY (US) | 1998-06-18 | — | — | WO | disclosed |
| WO-1995029892-A1 | HYDROXAMIC ACID AND AMINO ACID DERIVATIVES AND THEIR USE AS ANTI-ARTHRITIC AGENTS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1995-11-09 | — | — | WO | disclosed |